EDENRED S.A. : preparatory information and documents for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
35
EDENRED S.A. : preparatory information and documents for the AGM

Regulated information

Paris, April 12, 2017

 
    00 Month 0000
     
      PREPARATORY INFORMATION   AND DOCUMENTS FOR THE 2017 AGM  
 
 

Shareholders are invited to attend the Annual Shareholders Meeting, which will take place at 03:00 pm on May 04, 2017 at the Novotel Paris Est, 1 avenue de la République, 93170 Bagnolet, France. The Notice of Meeting, comprising the agenda and draft resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) on March 27, 2017, and the Convening Notice will be published in the BALO on April 14, 2017.

The documents required under the French Commercial Code are available to shareholders as of the date the Convening Notice is issued, in accordance with the applicable regulatory provisions:

  • Any shareholder holding registered shares may, up to the fifth day, inclusive, prior to the Annual Shareholders Meeting, request documents required under Article R.225-83 of the French Commercial Code, from the Company.  For shareholders holding bearer shares, the exercise of this right is subject to the submission of a shareholding certificate delivered by their financial intermediary;
  • All shareholders may consult documents required under Articles L. 225-115 and R.225-83 of the French Commercial Code, at the Company's headquarters during the two weeks preceding the date of the Meeting.

All documents are available at edenred.com, Investors / Shareholders section from this link

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...5b000118af

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors Urged to Act as Lawsuit Against Everus Builds

Updated Category News Views 97

Investigation of Claims Against Everus Construction Group Faruqi & Faruqi, LLP, a well-respected national securities law firm, has initiated an investigation into potential claims associated with Everus Construction Group, Inc. (NYSE: ECG). The firm specializes in shareholder rights and is aiming to provide support to affected investors after concerning revelations about...

Continue Reading
Heilongjiang Forum 2025: Elevating Macao's Global Tourism Standing

Updated Category News Views 107

Global Tourism Economy Forum 2025: A Landmark Event The Global Tourism Economy Forum (GTEF) made its notable debut outside of Macao by hosting the 2025 edition in Heilongjiang province, China. This forum gathered influential figures from the tourism sector and various related industries, fostering discussions aimed at exploring new avenues for cooperation and growth....

Continue Reading
Nextracker and T1 Energy Collaboration Drives Solar Growth

Updated Category News Views 198

Nextracker and T1 Energy Join Forces to Strengthen Solar Production Nextracker Inc. (NASDAQ: NXT) has recently established a partnership with T1 Energy Inc. (NYSE: TE) aimed at revolutionizing solar manufacturing. This collaboration will see the integration of Nextracker's cutting-edge steel module frame technology into T1 Energy's upcoming solar manufacturing plant,...

Continue Reading
Nathan Ballentine Steps In as Regional VP at New American Funding

Updated Category News Views 175

New Leadership at New American Funding New American Funding (NAF), a prominent independent mortgage lender, has announced a significant appointment. Nathan Ballentine is joining the team as the Regional Vice President, where he will play a pivotal role in propelling growth and development within the state. His expertise will be crucial as the company seeks to deepen its...

Continue Reading
CSL Behring Secures Approval for ANDEMBRY® in Japan

Updated Category News Views 341

CSL Behring's Recent Approval for ANDEMBRY® CSL Behring has announced a significant medical milestone with the approval of ANDEMBRY® (garadacimab) subcutaneous (S.C.) injection 200mg pens in Japan. This groundbreaking therapy is a first-in-class monoclonal antibody specifically designed to inhibit activated Factor XII (FXIIa), a crucial initiator in the hereditary...

Continue Reading